Gracell Biotechnologies Inc.
DelistedCIK 1826492fmd_09M38WK0DD9364P8YJVAAPH7Y8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2023, 8 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Research and development | 52 | 119 | 169 | 327 | 485 |
| Operating income | (63) | (147) | (214) | (464) | (625) |
| Interest expense | – | – | 2 | 5 | 7 |
| Interest and investment income | 1 | 4 | 3 | 9 | 24 |
| Other non-operating income (expense) | 0 | (0) | (0) | (0) | 0 |
| Income before taxes | (61) | (139) | (212) | (452) | (607) |
| Income tax expense | – | – | 0 | – | 0 |
| Net income from continuing operations | – | – | (212) | – | (608) |
| Net income | (61) | (139) | (212) | (452) | (608) |
| Net income to common shareholders | (73) | (201) | (275) | (454) | (608) |